News Agencies Feed 


Boehringer Ingelheim and CureVac Announce Collaboration to Develop Next Generation Lung Cancer Immunotherapy
September 19, 2014

  • Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202
  • CV9202 is based on CureVac’s mRNA technology (RNActive®)
  • Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting
  • The in-licensing of this investigational cancer compound adds a highly innovative...

    Continue Reading >

Saudi Arabia Makes MERS Preparations for Hajj
September 18, 2014

Last year, two people in Saudi Arabia had contracted a mysterious coronavirus just before the annual Hajj, raising fears of a SARS-like outbreak. That didn’t happen, but the virus, which causes a condition called Middle East Respirtory Syndrome (MERS), has been spreading. A year later, officials in Saudi Arabia are once again trying"...

Continue Reading >

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction in Blood Glucose in Phase III Study
September 16, 2014

Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were previously untreated. Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile"...

Continue Reading >

Mers virus: Saudi Arabia camel traders unalarmed by disease
September 15, 2014

Health officials in Saudi Arabia say they are doing all they can to avoid an outbreak of the new deadly Mers virus at this year's Hajj pilgrimage.

Middle East Respiratory Syndrome has killed just over 300 people in the Kingdom since it first emerged there in 2012.

Officials have been accused of not doing enough to contain the outbreak, but the country's acting health minister has told the BBC the situation is now"......

Continue Reading >

MoH warns of risks of contracting MERS-CoV from camels
September 14, 2014

The Ministry of Health issued an advisory on Saturday reminding the public to be cautious when dealing with camels because of the risk of contracting MERS Coronavirus.

The advisory comes as part of the ministry’s awareness campaign of the deadly virus ahead of the Haj pilgrimage when millions of people converge on the Kingdom from every part of the world.

Health Ministry spokesman Khalid Al-Mirghalani told Arab News on Saturday that recent studies have shown that MERS-CoV can be found in the mucus and saliva of infected...

Continue Reading >

Saudi gynecologist fined SR2.2m for medical errors
September 10, 2014

A Saudi female gynecologist working at the Gynecology and Maternity Hospital in Makkah was fined SR2.2 million for committing a series of medical errors, reported.

The Appeal Court in Makkah upheld the decision, which had earlier been issued by the Legal Health Authority, on the imposition of the fine.

Four years ago, the gynecologist was referred to the authority for investigation into several medical errors. The authority, accordingly, decided to fine her.

The doctor had appealed to the Chamber of Grievances...

Continue Reading >

No Saudi Ban Over Ebola For Nigerians Going On Haj: Arab News
September 9, 2014

Saudi Arabia, which has barred pilgrims from Sierra Leone, Liberia and Guinea from the haj due to Ebola concerns, will allow Nigerians to attend, an official was reported on Monday as saying, suggesting the smaller outbreak there was less worrying.

Guinea, Liberia and Sierra Leone have been worst hit by an outbreak of the disease in West Africa, with a combined death toll in those three countries since March of 2,097, as at Sept. 5, the World Health Organization"...

Continue Reading >

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting
September 9, 2014

  • 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance®
  • Abstracts on investigational empagliflozin/linagliptin combination tablet
  • Data on Lilly/BI’s investigational insulin glargine product
  • Abstracts on Trajenta® (linagliptin) and linagliptin in combination with metformin

Data to be presented at the European Association"...

Continue Reading >

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
September 8, 2014

  • Data show Spiriva® Respimat® reduced the risk of patients having a severe asthma exacerbation** by 21% when used as add-on therapy in patients who have symptoms despite taking current standard treatment†1
  • Almost one in two patients with asthma still experience symptoms while receiving current treatment options,2,3,4 putting them at increased risk of potentially life-threatening asthma exacerbations5
  • The regulatory acceptance of Spiriva® Respimat® in asthma establishes a new class of...

    Continue Reading >

TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD
September 8, 2014

European Respiratory Society International Congress 2014

  • First presentation of TONADO™ results for the only fixed-dose combination (FDC) containing tiotropium
  • Pivotal Phase III studies for tiotropium + olodaterol Respimat® FDC met lung function and quality of life primary endpoints†,1
  • Data support recent regulatory submissions in Europe and US for tiotropium + olodaterol Respimat® FDC


Continue Reading >